Allison R. Ayala

Allison R. Ayala

Auto-generated profile, based on publicly available information

Allison R. Ayala

Jaeb Center for Health Research, Tampa, FL, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Translational Vision Science & Technology
Verified
Journal Article
Open access
PDF file
DBDavid G. Birch
David G. Birch
PCPeiyao Cheng
Peiyao Cheng
JDJacque L. Duncan
Jacque L. Duncan
AAAllison R. Ayala
Allison R. Ayala
MMMaureen G. Maguire
Maureen G. Maguire
FGfor the Foundation Fighting Blindness Consortium Investigator Group
for the Foundation Fighting Blindness Consortium Investigator Group
Purpose: The purpose of this study was to evaluate baseline best corrected visual acuity (BCVA), full-field electroretinography (ERG), full-field stimulus thresholds (FST), and their relationship with baseline demographic and clinical characteristics in the Rate of Progression in Usher syndrome type 2 (USH2A)-related Retinal Degeneration (RUSH2A) multicenter study. Methods: Participants had Usher syndrome type 2 (USH2, N = 80) or autosomal recessive nonsyndromic retinitis pigmentosa (ARRP, N = 47) associated with biallelic variants in the USH2A gene. Associations of demographic and clinical characteristics with BCVA, ERG, and FST were assessed with regression models. Results: In comparison to ARRP, USH2 had worse BCVA (median 79 vs. 82 letters; P < 0.001 adjusted for age), lower rod-mediated ERG b-wave amplitudes (median 0.0 vs. 6.6 µV; P < 0.001) and 30 Hz flicker cone-mediated ERG amplitudes (median 1.5 vs. 3.1 µV; P = 0.001), and higher (white, blue, and red) FST thresholds (means [−26, −31, −23 dB] vs. [−39, −45, −28 dB]; P < 0.001 for all stimuli). After adjusting for age, gender, and duration of vision loss, the difference in BCVA between diagnosis groups was attenuated (P = 0.09). Only diagnosis was associated with rod- and cone-mediated ERG parameters, whereas both genders (P = 0.04) and duration of visual loss (P < 0.001) also were associated with FST white stimulus. Conclusions: USH2 participants had worse BCVA, ERG, and FST than ARRP participants. FST was strongly associated with duration of disease; it remains to be determined whether it will be a sensitive measure of progression. Translational Relevance: Using standardized research protocols in RUSH2A, measures have been identified to monitor disease progression and treatment response and differentiate features of prognostic relevance between USH2 and ARRP participants with USH2A mutations.

22 May 2020 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
JDJacque Duncan
Jacque Duncan
WLWendi Liang
Wendi Liang
MMMaureen G. Maguire
Maureen G. Maguire
IAIsabelle Audo
Isabelle Audo
AAAllison R. Ayala
Allison R. Ayala
JSJosé-Alain Sahel
José-Alain Sahel

22 August 2022 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
ELEleonora M. Lad
Eleonora M. Lad
JDJacque Duncan
Jacque Duncan
WLWendi Liang
Wendi Liang
MMMaureen G. Maguire
Maureen G. Maguire
AAAllison R. Ayala
Allison R. Ayala
SFSina Farsiu
Sina Farsiu

21 March 2022 in Human Mutation
Verified
Journal Article
Closed access
RHRobert B Hufnagel
Robert B Hufnagel
WLWendi Liang
Wendi Liang
JDJacque L. Duncan
Jacque L. Duncan
CBCarmen C. Brewer
Carmen C. Brewer
IAIsabelle Audo
Isabelle Audo
FGfor the Foundation Fighting Blindness Consortium Investigator Group
for the Foundation Fighting Blindness Consortium Investigator Group

1 October 2024 in Translational Vision Science & Technology
Verified
Journal Article
Open access
PDF file
MMMaureen G. Maguire
Maureen G. Maguire
DBDavid G. Birch
David G. Birch
JDJacque L. Duncan
Jacque L. Duncan
AAAllison R. Ayala
Allison R. Ayala
LALauren N. Ayton
Lauren N. Ayton
TGthe Foundation Fighting Blindness Clinical Consortium Investigator Group
the Foundation Fighting Blindness Clinical Consortium Investigator Group
Purpose: To evaluate functional and structural assessments as endpoints for clinical trials for USH2A-related retinal degeneration. Methods: People with biallelic disease–causing variants in USH2A, visual acuity ≥ 20/80, and visual field ≥ 10° diameter were enrolled in a 4-year, natural history study. Participants underwent static perimetry, microperimetry, visual acuity, fullfield stimulus testing (FST), and optical coherence tomography annually. Rates of change estimated from mixed-effects linear models and percentages of eyes with changes exceeding the coefficient of repeatability (CoR) or thresholds conforming with U.S. Food and Drug Administration (FDA) guidelines were evaluated. Results: Rates of change were generally more sensitive to change than proportions of eyes exceeding a threshold such as the CoR. Baseline ellipsoid zone area ≥ 3 mm2 was necessary to detect change. Mean sensitivity and volumetric hill of vision measures on static perimetry had similar properties and were the most sensitive to changes of the continuous measures. The highest 4-year proportions of eyes exceeding the CoR were from FST testing (47%) and microperimetry (32%). Specification of loci as functional transition points (FTPs) resulted in 45% (static perimetry) and 46% (microperimetry) at 4 years, meeting FDA guidelines for progression. Conclusions: Rate of change of mean sensitivity on static perimetry was a sensitive perimetric continuous measure. Percentages of within-eye change were largest with FST testing and microperimetry. FTPs appear to be particularly sensitive to change. These results affect clinical trial design for USH2A-related retinal degeneration. Translational Relevance: Analyses of natural history data from the Rate of Progression in USH2A-Related Retinal Degeneration (RUSH2A) study can inform eligibility criteria and endpoints for clinical trials.

2 March 2022 in Investigative Ophthalmology & Visual Science
Verified
Journal Article
Open access
PDF file
DBDavid G. Birch
David G. Birch
LSLassana Samarakoon
Lassana Samarakoon
MMMichele Melia
Michele Melia
JDJacque L. Duncan
Jacque L. Duncan
AAAllison R. Ayala
Allison R. Ayala
FGfor the Foundation Fighting Blindness Consortium Investigator Group
for the Foundation Fighting Blindness Consortium Investigator Group
Purpose: To measure visual fields using two-color dark-adapted chromatic perimetry in a subset of participants in the Rate of Progression of USH2A-related Retinal Degeneration (RUSH2A), a study of USH2A-mediated syndromic (USH2) and autosomal recessive nonsyndromic retinitis pigmentosa, determine percentage retaining rod function, and explore relationships between dark-adapted visual fields (DAVF) and rod function from ERG and full-field stimulus thresholds (FST). Methods: Full-field rod mean sensitivity, number of rod loci, maximum sensitivity, DAVF full-field hill of vision (DAVF VTOT), and 30° hill of vision (DAVF V30) were measured in one eye for DAVF ancillary study participants (n = 49). Loci where cyan relative to red sensitivity was more than 5 dB on dark-adapted chromatic perimetry were considered rod mediated. Correlation coefficients between the DAVF measures and standard clinical measures were estimated, as were kappa statistics (κ) for agreement between DAVF and other measures of rod function. Results: Of 49 participants tested with DAVF, 38 (78%) had evidence of rod function, whereas 15 (31%) had measurable rod ERGs. DAVF maximum sensitivity was highly correlated with FST white thresholds (r = −0.80; P < .001). Although not statistically significant, the number of rod loci and DAVF VTOT were lower in eyes with longer disease duration by 0.82 (95% confidence interval, −1.76, 0.12) loci/year and 0.59 (95% confidence interval, −1.82, 0.64) dB-steradians/year, respectively. Conclusions: Rod-mediated function on FST and DAVF is present in many patients with symptomatic USH2A-related retinal degeneration, including some without measurable rod ERGs. RUSH2A longitudinal data will determine how these measures change with disease progression and whether they are useful for longitudinal studies in inherited retinal degenerations.